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Abstract  In  the  PSA  era,  the  incidence  of  localized  prostate  cancer  has  been  increasing.  This
reality requires  new  therapeutic  strategies,  in  order  to  give  an  answer  to  patients,  in  whom
active surveillance  may  be  indicate  but  desire  more  interventionist  strategy  with  minimal  side
effects and  without  compromising  cancer  control.  In  these  cases,  focal  therapies  that  include
irreversible  electroporation  may  be  effective  alternative  strategies.  The  irreversible  electropo-
ration is  an  emergent  approach  on  focal  treatment  of  localized  PCa.  The  nonthermal  mechanism
that preserves  the  tissue  architecture  without  damaging  tissue  structures,  such  as  vessels  and
nerves within  the  target  region,  is  the  main  advantage  comparatively  to  other  techniques  used
in focal  treatment.  The  number  of  clinical  studies  is  reduced  and  the  results  still  immature.
© 2016  Associac¸a˜o  Portuguesa  de  Urologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
PALAVRAS-CHAVE Terapêuticas  focais  no  tratamento  do  carcinoma  da  próstata  localizado:  o  papel  da
Carcinoma  da
próstata;
eletroporac¸ão  irreversível  --  presente  ou  futuro?Terapêutica  focal;
Tratamento  focal;
Eletroporac¸ão
Resumo  Na  era  do  PSA,  a  incidência  do  carcinoma  da  próstata  localizado  tem  vindo  a  aumen-
tar. Esta  realidade  exige  novas  estratégias  terapêuticas,  a  ﬁm  de  poder  dar  uma  resposta
aos pacientes,  os  quais,  embora  esteja  indicada  a  vigilância  ativa,  desejam  uma  estratégia
mais interventiva  com  poucos  efeitos  adversos  e  sem  compromisso  do  controlo  da  doenc¸a.∗ Corresponding author.
E-mail address: brunoalexpereira@gmail.com (B.J. Pereira).
ttp://dx.doi.org/10.1016/j.acup.2016.10.001
341-4022/© 2016 Associac¸a˜o Portuguesa de Urologia. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Irreversible  electroporation:  present  or  future?  105
Nestes  casos,  as  terapêuticas  focais,  que  incluem  a  eletroporac¸ão  irreversível,  podem  ser  uma
estratégia  alternativa  efetiva.  A  eletroporac¸ão  irreversível  constitui  uma  abordagem  emergente
no tratamento  do  carcinoma  da  próstata  localizado.  O  mecanismo  de  lesão  celular  não-térmico
que preserva  a  arquitetura  tecidular  sem  lesão  de  estruturas,  tais  como  vasos  e  nervos  dentro
da região  alvo,  constitui  a  principal  vantagem  comparativamente  com  as  outras  técnicas  uti-
lizadas no  tratamento  focal.  O  número  de  estudos  clínicos  é  reduzido  e  os  resultados  ainda  são
imaturos.
© 2016  Associac¸a˜o  Portuguesa  de  Urologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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sIntroduction
In  industrialized  countries,  the  prostate  cancer  (PCa)  is
the  most  common  cancer  among  men  over  50  years.1
The  incidence  is  highest  in  Northern  and  Western  Europe
(>200/100,000),  while  rates  in  Eastern  and  Southern  Europe
have  showed  a  continuous  increase  and  appear  to  be  reach-
ing  the  levels  seen  in  Northern  and  Western  Europe.2
Although  the  incidence  has  increased  in  all  parts  of  Europe,
this  phenomenon  is  most  notable  in  Northern  Europe  and  in
the  youngest  group  (35--64  years).2
PCa  is  currently  diagnosed  in  15--20%  of  men  during  their
lifetime,  but  the  lifetime  risk  of  death  from  PCa  is  only
3%.3 The  mortality  attributable  to  this  pathology  tends  to
range  widely  from  country  to  country  in  the  industrialized
world.3 In  most  Western  countries,  mortality  rates  due  to
PCa  have  been  decreasing,  with  varying  rates  across  the  dif-
ferent  nations.4 In  Europe,  during  last  decade,  the  5-year
relative  survival  percentages  for  prostate  cancer  steadily
increased  from  73.4%  in  1999--2001  to  83.4%  in  2005--2007,
despite  having  identiﬁed  discrepancies  between  countries  of
Eastern  Europe  and  the  rest  of  Europe.5 Likewise,  the  United
States  of  America  has  recorded  a  similar  trend  in  mortality,
condition  for  which  aggressive  PCa  screening  policy  has  had
a  preponderant  role.4
Currently,  PCa  screening  using  PSA  has  contributed  to
the  increasing  the  number  of  cases  diagnosed  at  an  earlier
stage.  Together  with  the  improvement  of  imaging  techniques
and  biopsy,1 the  incidence  of  localized,  small  volume  and
low  grade  PCa  has  increased  substantially.6 In  these  cases,
active  surveillance  appears  to  be  a  feasible  management
strategy  in  carefully  selected  patients.  However,  18%  of  men
on  active  surveillance  choose  a  radical  approach  due  to
anxiety.3 On  the  other  hand,  despite  technological  progress
in  surgery  and  radiotherapy,  the  occurrence  of  side  effects
remains  considerably  high.6
Although  in  experimental  phase,  focal  therapy  using
the  most  diverse  techniques  has  gained  preponderance  by
minimizing  damages  on  the  remaining  gland  and  surrounding
structures,  while  retaining  the  therapeutic  beneﬁts6 and
without  commitment  of  the  life  expectancy.7 This  strategy
is  an  approach  similar  to  that  already  done  in  the  treatment
of  solid-organ  malignancies,  such  renal,  thyroid,  breast,
liver  and  pancreas.6
r
c
oThere  is  evidence  that  the  natural  history  of  the  disease  is
ainly  driven  by  a  lesion  of  large  size  and  high  grade  called
ndex  lesion,6 justifying  this  approach.
The  high  intensity  focused  ultrasound  (HIFU)  and
ryotherapy  are  the  most  studied  techniques.  Others,  such
s  photothermal  laser,  photodynamic  therapy  and  focal
rachytherapy,  have  been  studied  as  plausible  approaches  to
artial  ablation  of  the  prostate  gland.  Recently,  irreversible
lectroporation  (IE)  appears  to  be  a  technique  with  enough
otential  to  focal  treatment  of  PCa.
aterials and methods
 literature  search  was  done  on  PubMed  and  ScienceDi-
ect  databases  using  the  keywords  ‘‘prostate  cancer’’,
‘prostatic  neoplasms’’,  ‘‘focal  treatment’’,  ‘‘focal  ther-
py’’,  ‘‘irreversible  electroporation’’.  The  articles  included
ere  published  between  01/01/2004  and  31/12/2014.  Ori-
inal  articles,  review  articles  and  clinical  trials  conducted
n  humans  were  included.  In  each  study,  the  following
ata  were  extracted:  characteristics  of  target  population,
isease  control  outcomes,  side  effects  and  preservation  of
rinary  continence  and  erectile  function  after  treatment.
rreversible electroporation
rinciples  and  clinical  applicability
he  IE,  used  in  the  food  industry  for  sterilization,  emerged
s  a  new  method  for  minimally  invasive  tumour  ablation.8
he  bases  that  have  contributed  to  this  evolution  naturally
erived  of  reversible  electroporation,  which  has  been  used
ainly  as  a research  tool  in  the  medical  ﬁeld  to  promote  the
ransmembrane  transport  of  genes,  antibodies,  RNA,  DNA,
nd  even  drugs  (e.g.:  cytostatics).8--10 Then,  an  electrical
eld  that  transiently  increases  the  porosity  of  the  mem-
rane  facilitates  the  exchange  of  substances.8 In contrast,
n  IE  an  electrical  ﬁeld  of  much  higher  voltage  is  applied,
hich  leads  to  permanent  nanopore  formation  in  the  cell
embrane,  with  disruption  of  cellular  homeostasis  and,  con-
equently,  cell  death  by  apoptosis.8,9,11,12 The  dead  cells  are
emoved  by  the  immune  system  and  replaced  through  me-
hanisms  of  innate  cellular  regeneration.  The  preservation
f  the  surrounding  tissue  architecture  allows  fast  activation
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f  the  immune  system  and  consequent  elimination  of  dead
ells,  but  also  tissue  regeneration,  avoiding  scar  formation.8
owever,  if  the  energy  applied  is  high  enough  to  induce
hermal  damage,  it  can  cause  denaturation  of  proteins  and
ollagen  and,  ultimately,  tissue  necrosis.12
A  single  bipolar  electrode  or  multiple  unipolar  electrodes
laced  and  activated  in  pairs  are  necessary  requirements  for
echnical  implementation.  Owing  to  the  relatively  small  size
f  each  ablation  zone,  multiple  electrodes  are  required.8
he  magnitude  of  the  electric  ﬁeld,  necessary  to  achieve
he  therapeutic  effect,  is  inﬂuenced  by  spacing  and  rela-
ive  positions  of  the  several  electrodes8 and  by  the  duration
nd  interval  between  the  electric  pulses.12 Furthermore,
he  size  of  cells  and  tissue  density  are  variables  to  take  in
ccount.10
During  the  ablation  procedure,  strictly  deﬁned  areas  are
ormed,  thus  allowing  an  immediate  monitoring  of  the  area
reated  by  MRI  and  ultrasound.11
The  presence  of  intense  muscle  contractions,  caused
y  the  high-voltage  electrical  pulses,  requires  gen-
ral  anaesthesia  with  complete  neuromuscular  blockade.8
evertheless,  the  presence  of  small  muscle  contractions
bliges  for  a  constant  check  in  the  location  of  electrodes,8
n  order  to  avoid  injuries  to  healthy  structures.1,13 A  close
onitoring  of  the  cardiac  rhythm  and  synchronization  of  the
E  pulses  with  ECG  is  also  mandatory.  Although  arrhythmias
re  rare,  they  can  lead  to  haemodynamic  disturbance,  hence
he  need  for  an  invasive  monitoring  of  the  blood  pressure.8
IE  is  not  limited  by  the  disadvantages  of  the  heating  or
ooling  techniques  and  could  virtually  overcome  some  of  the
eﬁciencies  inherent  to  those  techniques.8,9 The  results  of
reclinical  and  clinical  studies  published  makes  this  tech-
ique  a  potential  very  reasonable  option  for  the  treatment
f  a  large  variety  of  tumours,  including  periportal  liver
asses,  pancreatic  cancer,  perihilar  renal  tumours,  PCa  and
ther  soft  tissue  tumours.8
The  indications  and  contraindications  are  not  fully
nown.  The  inability  to  destroy  large  volume  of  tissue  cons-
itutes  a  major  limitation  of  this  technique,  a  problem
hat  could  eventually  be  suppressed  by  the  use  of  multiple
robes8,9 or  by  the  addition  of  chemotherapeutic  or  cyto-
oxic  agents,9 in  spite  of  increasing  the  complexity  of  the
rocedure.  Similarly,  inaccessible  lesions  cannot  be  treated
y  this  way.8 This  procedure  is  contraindicated  in  patients
ith  cardiac  arrhythmias  or  any  condition  that  promotes
heir  development  (e.g.:  electrolyte  disorders),  as  well  as
hose  who  cannot  be  subjected  to  general  anaesthesia.8
Given  the  particularities  described  herein,  this  technique
ay  be  an  acceptable  alternative  in  the  primary  treatment
f  PCa.12
linical  outcomes
he  clinical  experience  of  IE  on  PCa  in  humans  is  scarce.
The  ﬁrst  study,  published  by  Brausi  et  al.14 in  2011,
evealed  the  provisional  results  related  to  application  of  IE
n  11  men  with  mean  age  of  70.2  years.  All  men  had  low  risk
isease  --  10  were  staged  with  T1c  and  1  was  staged  with
2a.  The  preoperative  mean  value  of  PSA  was  6.43  ng/mL.
here  were  no  reported  complications.  The  study  stated  a
ollow-up  around  19  months,  with  PSA  determination  and
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onitoring  of  urinary  symptoms  (IPSS)  and  erectile  func-
ion  (IIEF)  at  14th,  30th,  90th  and  525th  day.  Only  1  patient
ad  acute  urinary  retention,  while  3  patients  had  transient
rge  incontinence.  The  mean  PSA  values  were  3.5  ng/mL;
.9  ng/mL;  3.3  ng/mL;  and  3.12  ng/mL.  The  continence  rate
as  100%.  IPSS  was  reduced  to  7.72;  7;  6.12;  4.28  and  4
espectively,  while  IIEF  was  13.18;  10.45;  10.5;  11  and  17.3.
iopsies  made  30  days  after  EI  were  negative  in  8  (73%)
atients.  Three  patients  (27%)  had  persistent  adenocarci-
oma.
In  2013,  Dickinson  et  al.15 published  a  study  of  15  men
ith  low  (7%),  medium  (80%)  and  high  (13%)  risk  disease  that
eceived  focal  IE  between  August  2011  and  September  2012.
E  was  received  as  primary  treatment  in  9  men  and  as  a
alvage  procedure  in  6.  Mean  age  was  65  years  and  mean
SA  was  5.9  ng/mL.  During  the  procedure  there  were  no
omplications.  Four  men  (27%)  had  grade  1  and  3  had  grade  2
ostoperative  adverse  events.  There  were  no  severe  adverse
vents.  Continence  and  erectile  function  were  preserved  in
ll  patients  with  available  data.
Valerio  et  al.16 presented  in  2014  a  pilot  study  where
he  toxicity  proﬁle  of  IE  in  the  focal  treatment  of  PCa  was
easured.  This  was  a  retrospective  multicenter  study  that
ncluded  34  men  with  low  (26%),  intermediate  (71%)  and  high
3%)  risk  disease.  In  this  analysis,  all  patients  received  EI
s  primary  treatment.  The  mean  age  was  65  years  and  the
ean  PSA  was  6.1  ng/mL.  There  were  no  cases  of  severe
oxicity  during  the  6  months  of  follow-up.  Twelve  (35%)  and
0  (29%)  patients  had  grade  1  and  2  complications,  respec-
ively.  Six  (18%)  patients  had  debris  and/or  haematuria  and
 (15%)  had  dysuria.  Five  patients  developed  uncomplicated
rinary  tract  infection  and  only  2  patients  had  urinary  reten-
ion.  In  4  men  did  not  occur  genito-urinary  adverse  events.
n  the  follow-up  period,  mpMRI  show  suspicious  residual
isease  in  6  patients,  of  whom  2  remain  on  surveillance.
econdary  local  treatment  was  needed  in  4  (12%)  men.  From
unctional  view,  100%  (24/24)  patients  were  continent  and
otency  was  preserved  in  95%  (19/20).  According  to  these
uthors,  prostate  posterior  tumours  close  to  the  rectum  may
e  a  contraindication  to  electroporation  given  its  potential
ncreased  risk  for  rectal  lesions.
iscussion
he  concept  of  focal  therapy  is  still  controversial.  To
ome  researchers  this  approach  includes  only  the  focus
reatment,17 to  others,  any  approach  able  to  preserve  part
f  prostatic  tissue  (e.g.:  ‘‘hockey  stick’’  ablation,  hemiab-
ation  and  focal  ablation)  maybe  considered  focal  therapy.6
part  from  these  considerations,  focal  therapies  are  emerg-
ng  treatment  modalities  for  localized  PCa.
In  PSA’s  era,  the  number  of  new  PCa  diagnosed  at  early
tage  has  become  a  reality.  In  men  with  low  risk  disease,
uropean  Urology  Association  accepts  active  surveillance
level  of  evidence  2a,  grade  of  recommendation  A).3 How-
ver,  focal  therapies  are  alternatives  to  active  surveillance
mong  anxious  patients  who  request  active  treatment.18urrently,  the  radical  approach,  such  as  radical  prosta-
ectomy,  external  radiotherapy  or  brachytherapy,  is  the
old  standard  for  the  treatment  of  PCa.  The  considerable
orbidity  of  such  strategies,  which  translates  into  erectile
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dysfunction,  incontinence  and  rectal  toxicity  (50%,  10%  and
10%,  respectively),1 fostered  the  growing  interest  of  the
scientiﬁc  community  around  focal  therapies.6 These  permit
to  destroy  the  tumour  and  sparing  healthy  surrounding
tissues  such  as  neurovascular  bundles  and  external  urinary
sphincter  and  achieve  the  coveted  Trifecta  Outcome  (pad-
free  continence,  erections  sufﬁcient  for  penetration  with
or  without  oral  PDE5-I  and  disease  control).6
The  index  lesion,  which  is  generally  deﬁned  as  the  largest
volume  lesion  with  higher  grade,  is  the  target  of  any  focal
therapy.  It  is  postulated  that  selective  destruction  of  this
lesion  prevents  cancer  progression.18 Evaluation  of  biolo-
gical  behaviour  of  any  lesion  through  its  volume  is  a  poor
strategy,  even  that  lesions  with  small  size  have  better
prognosis.19 Although  PCa  is  a  multifocal  disease,  multiple
small  foci  may  represent  clinically  insigniﬁcant  disease  that
are  unlikely  to  progress  and  impact  on  quality  of  life.19 Sur-
prisingly,  the  study  of  Haffner  et  al.20 prove  that  the  lethal
clone  comes  from  small  and  low  grade  focus  in  the  primary
tumour.
Proper  identiﬁcation  of  ideal  patient  for  focal  therapy
is  undoubtedly  one  of  the  greatest  challenges.19 The  loca-
lization  and  characterization  through  biopsy  and  imaging
techniques  is  the  foundation  of  the  whole  process.  Prostate
biopsy  guided  by  TRUS  is  the  modality  most  used  in  the
diagnosis  of  PCa,  although  the  same  cannot  predict  the
extent  of  the  tumour  on  ﬁnal  pathological  specimen.19,21
Even  saturation  biopsies  fail  when  a  more  detailed  char-
acterization  of  extent  of  the  disease  is  desired.19,21
The  template  prostate  mapping  biopsy  (TPMB)  is  widely
accepted  by  various  consensus  groups  and  with  proven
value  in  several  studies.19,21 Recent  data  have  shown  that
multiparametic  MRI  is  able  to  detect  clinically  signiﬁcant,
high-grade  tumours  with  high  accuracy  when  using  TPMB  as
the  reference  standard.19
There  are  no  standardized  criteria  to  deﬁne  persistence
or  progression  of  the  cancer.18 Although  measurement  of
PSA  is  recommended  during  follow-up,  the  role  of  this
biomarker  is  not  established  due  to  the  lack  of  consensus
about  the  deﬁnition  of  biochemical  recurrence.6,19,22 In
studies  reported  there  were  no  established  criteria  to
deﬁne  biochemical  recurrence.
Until  now  there  is  no  consensus  about  the  deﬁnition  of
disease  control.  The  existence  of  higher  Gleason  grade  can-
cer,  the  persistence  of  cancer  with  similar  or  lower  grade
after  repeat  focal  therapy  in  the  same  area  or  the  need  for
additional  PCa  treatment  other  than  focal  therapy  is  deﬁned
as  therapeutic  failure  by  the  International  Multidisciplinary
on  Trial  Design.23 In  the  reported  studies  only  reference  was
made  to  the  number  of  individuals  with  positive  biopsy.
A  presumed  but  unproven  advantage  of  focal  therapy
is  the  lower  likelihood  and  severity  of  treatment  related
morbidity.19 Although  the  number  of  subjects  in  each  study
is  reduced,  the  main  complications  reported  were  transient
urge  incontinence,  persistent  debris  hematuria  and  acute
urinary  retention.  In  the  available  studies  of  Brausi  et  al.,14
Dickinson  et  al.15 and  Valerio  et  al.16 all  men  remained  conti-
nent  after  treatment.  Similarly,  erectile  function  remained
unchanged  in  2  studies.14,15 Noteworthy,  at  study  of  Brausi
et  al.14 IIEF-5  score  before  treatment  was  16.8  and  at  the
last  assessment  was  17.3.  At  study  of  Valerio  et  al.16
the  erectile  function  was  preserved  in  95%  of  patients.107
The  knowledge  about  the  clinical  application  of  IE  in
he  treatment  of  PCa  is  very  limited,  which  does  not  allow
onﬁrming  whether  this  provides  equally  convincing  out-
omes  as  those  obtained  in  the  more  studied  techniques
uch  as  HIFU  and  cryotherapy.  This  approach  seems  to  have
ome  advantages  over  the  other  techniques.  In  thermal  abla-
ion,  tissue  heating  or  freezing  frequently  correlates  with
evastating  complications  in  adjacent  vital  organs,  such  as
owel,  ductal  structures  and  critical  vascular  supply.  In  the-
ry,  these  disadvantages  maybe  avoided  in  IE  owing  to  its
onthermic  mechanism  that  preserves  the  tissue  architec-
ure  without  damaging  surrounding  structures,  vessels  and
erves.8,9
On  the  other  hand,  the  safety  and  efﬁcacy  proﬁles  of  the
E  are  still  largely  unknown.8 Furthermore,  this  approach
oes  not  allow  the  destruction  of  large  volumes  of  tissue
nder  a safe  electric  ﬁeld.8,9 People  without  intact  immune
ystem  may  beneﬁt  less  from  this  approach.11
onclusion
E  stays  in  its  infancy  in  the  focal  treatment  of  PCa.
urrently,  the  experience  is  very  limited  and  follow-up
s  immature.  In  the  future,  more  robust  studies  will  be
equired  to  enable  a comparison  with  other  techniques  used
n  focal  treatment  of  localized  PCa  as  well  as  traditional
pproaches.
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